IL190842A0 - Use of sdf-1 for the treatment and/or prevention of neurological diseases - Google Patents

Use of sdf-1 for the treatment and/or prevention of neurological diseases

Info

Publication number
IL190842A0
IL190842A0 IL190842A IL19084208A IL190842A0 IL 190842 A0 IL190842 A0 IL 190842A0 IL 190842 A IL190842 A IL 190842A IL 19084208 A IL19084208 A IL 19084208A IL 190842 A0 IL190842 A0 IL 190842A0
Authority
IL
Israel
Prior art keywords
sdf
prevention
treatment
neurological diseases
neurological
Prior art date
Application number
IL190842A
Original Assignee
Proudfoot Amanda
Boschert Ursula
Vitte Pierre Alain
Serono Lab
Kadi Linda
Wojcik Jerome
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2006/067949 external-priority patent/WO2007051785A2/en
Application filed by Proudfoot Amanda, Boschert Ursula, Vitte Pierre Alain, Serono Lab, Kadi Linda, Wojcik Jerome filed Critical Proudfoot Amanda
Publication of IL190842A0 publication Critical patent/IL190842A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL190842A 2005-10-31 2008-04-14 Use of sdf-1 for the treatment and/or prevention of neurological diseases IL190842A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05110206 2005-10-31
US73414205P 2005-11-07 2005-11-07
PCT/EP2006/067949 WO2007051785A2 (en) 2005-10-31 2006-10-30 Use of sdf-1 for the treatment and/or prevention of neurological diseases

Publications (1)

Publication Number Publication Date
IL190842A0 true IL190842A0 (en) 2008-11-03

Family

ID=38006228

Family Applications (1)

Application Number Title Priority Date Filing Date
IL190842A IL190842A0 (en) 2005-10-31 2008-04-14 Use of sdf-1 for the treatment and/or prevention of neurological diseases

Country Status (2)

Country Link
EC (1) ECSP088411A (en)
IL (1) IL190842A0 (en)

Also Published As

Publication number Publication date
ECSP088411A (en) 2008-05-30

Similar Documents

Publication Publication Date Title
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
IL191795A0 (en) The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
EP1968607A4 (en) Treatment of cancer and other diseases
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
ZA200801706B (en) Methods and compositions for the prevention and treatment of kidney disease
AP2007004245A0 (en) Compounds and methods for the treatment or prevention of flavivirus infections
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
ZA200708819B (en) Methods and compositions for the prevention and treatment of kidney disease
EP1680145A4 (en) Methods and compositions for the treatment of neurological disease
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
IL187405A0 (en) Methods and compositions for the treatment of pain
ZA200800981B (en) Use of SDF-1 for the treatment and/or prevention of neurological diseases
ZA200707955B (en) Methods and pharmaceutical compositions for the treatment of neurological damage
GB0523961D0 (en) The treatment of ophthalmic diseases
EP1740221A4 (en) Methods and compositions for the treatment of polycystic diseases
IL188010A0 (en) Procedure for the treatment of purines and products thereof
SI1812797T1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
EP1781318A4 (en) Methods and compositions for the treatment of polycystic diseases
IL190842A0 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
IL180526A (en) Composition for the prevention and treatment of allergic inflammatory disease
GB0523964D0 (en) The treatment of ophthalmic diseases
GB0513413D0 (en) The treatment of inflammatory disorders and pain